Article 5WFPD Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022

by
from Morbidity and Mortality Weekly Report (MMWR) on (#5WFPD)
This report describes a recommendation for using a 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis.
External Content
Source RSS or Atom Feed
Feed Location http://www2c.cdc.gov/podcasts/createrss.asp?t=r&c=5
Feed Title Morbidity and Mortality Weekly Report (MMWR)
Feed Link https://www.cdc.gov/mmwr/index.html
Reply 0 comments